 Dara Aisner
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 66 | 2025 | 2329 | 5.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 45 | 2025 | 1046 | 3.880 |
Why?
| | Genetic Testing | 9 | 2022 | 427 | 2.310 |
Why?
| | ErbB Receptors | 22 | 2025 | 603 | 2.290 |
Why?
| | Mutation | 41 | 2025 | 3700 | 2.180 |
Why?
| | Pathology, Molecular | 7 | 2019 | 25 | 2.070 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 198 | 1.960 |
Why?
| | Protein Kinase Inhibitors | 26 | 2025 | 872 | 1.820 |
Why?
| | High-Throughput Nucleotide Sequencing | 14 | 2023 | 485 | 1.810 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 97 | 1.610 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 215 | 1.420 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 634 | 1.390 |
Why?
| | Neoplasms | 12 | 2023 | 2475 | 1.390 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 430 | 1.340 |
Why?
| | Biomarkers, Tumor | 18 | 2024 | 1185 | 1.190 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 221 | 1.100 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 159 | 1.090 |
Why?
| | Antineoplastic Agents | 16 | 2024 | 2060 | 1.080 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 259 | 1.040 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 750 | 0.960 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 74 | 0.940 |
Why?
| | Acrylamides | 5 | 2025 | 58 | 0.830 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 753 | 0.830 |
Why?
| | Gene Rearrangement | 13 | 2019 | 146 | 0.830 |
Why?
| | Adenocarcinoma | 9 | 2018 | 889 | 0.810 |
Why?
| | Molecular Targeted Therapy | 11 | 2024 | 387 | 0.760 |
Why?
| | Ganglioglioma | 4 | 2014 | 31 | 0.760 |
Why?
| | Brain Neoplasms | 10 | 2018 | 1164 | 0.750 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 386 | 0.720 |
Why?
| | Aniline Compounds | 4 | 2025 | 98 | 0.700 |
Why?
| | Precision Medicine | 4 | 2018 | 384 | 0.680 |
Why?
| | Humans | 122 | 2025 | 129116 | 0.670 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 75 | 0.650 |
Why?
| | Pyrazoles | 10 | 2018 | 405 | 0.650 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 96 | 0.650 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 5 | 0.640 |
Why?
| | Immunohistochemistry | 10 | 2023 | 1671 | 0.640 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 16 | 0.640 |
Why?
| | Prognosis | 14 | 2024 | 3788 | 0.640 |
Why?
| | Biological Products | 1 | 2022 | 200 | 0.630 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1573 | 0.630 |
Why?
| | Astrocytoma | 3 | 2015 | 121 | 0.620 |
Why?
| | Neoplasm Metastasis | 10 | 2024 | 616 | 0.620 |
Why?
| | Insurance Coverage | 1 | 2020 | 222 | 0.600 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 313 | 0.580 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 8 | 0.570 |
Why?
| | Computational Biology | 4 | 2023 | 598 | 0.560 |
Why?
| | RNA | 5 | 2019 | 883 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 508 | 0.500 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 89 | 0.470 |
Why?
| | Neoplasm Staging | 13 | 2024 | 1293 | 0.470 |
Why?
| | Smoking | 3 | 2018 | 1466 | 0.450 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7064 | 0.450 |
Why?
| | Pyrimidines | 6 | 2025 | 445 | 0.440 |
Why?
| | ras Proteins | 5 | 2015 | 145 | 0.440 |
Why?
| | Pyridines | 8 | 2016 | 477 | 0.430 |
Why?
| | Mesothelioma | 2 | 2024 | 38 | 0.430 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 963 | 0.420 |
Why?
| | Aged | 32 | 2025 | 22083 | 0.400 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 190 | 0.400 |
Why?
| | Male | 52 | 2025 | 63194 | 0.380 |
Why?
| | Female | 53 | 2025 | 68510 | 0.380 |
Why?
| | Middle Aged | 40 | 2025 | 31074 | 0.370 |
Why?
| | Telomerase | 7 | 2002 | 231 | 0.370 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 380 | 0.360 |
Why?
| | Neoadjuvant Therapy | 3 | 2024 | 381 | 0.360 |
Why?
| | S100 Proteins | 2 | 2014 | 40 | 0.360 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 23 | 0.350 |
Why?
| | Genomics | 4 | 2023 | 716 | 0.340 |
Why?
| | Sulfones | 3 | 2015 | 109 | 0.320 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 372 | 0.320 |
Why?
| | Curriculum | 1 | 2016 | 925 | 0.320 |
Why?
| | Glycine | 3 | 2015 | 165 | 0.320 |
Why?
| | Laboratories | 2 | 2023 | 109 | 0.310 |
Why?
| | Adult | 35 | 2025 | 35510 | 0.300 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 83 | 0.290 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 534 | 0.290 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 54 | 0.280 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 81 | 0.280 |
Why?
| | Treatment Outcome | 12 | 2024 | 10226 | 0.280 |
Why?
| | Indoles | 5 | 2025 | 372 | 0.270 |
Why?
| | Oncogene Fusion | 2 | 2019 | 13 | 0.270 |
Why?
| | Gene Dosage | 2 | 2018 | 142 | 0.270 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 52 | 0.270 |
Why?
| | Exons | 5 | 2019 | 338 | 0.260 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 174 | 0.260 |
Why?
| | Survival Analysis | 5 | 2025 | 1265 | 0.260 |
Why?
| | Melanoma | 2 | 2020 | 752 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2267 | 0.250 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 357 | 0.250 |
Why?
| | Oncogenes | 3 | 2016 | 109 | 0.250 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 9 | 0.240 |
Why?
| | Receptor, ErbB-2 | 4 | 2022 | 336 | 0.240 |
Why?
| | Immunotherapy | 5 | 2022 | 588 | 0.240 |
Why?
| | Pemetrexed | 1 | 2024 | 32 | 0.230 |
Why?
| | Epithelioid Cells | 2 | 2015 | 8 | 0.230 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1825 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.220 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 621 | 0.210 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 3184 | 0.210 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.210 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 9 | 0.210 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 147 | 0.200 |
Why?
| | Pathologists | 2 | 2023 | 17 | 0.200 |
Why?
| | Young Adult | 13 | 2024 | 12389 | 0.200 |
Why?
| | Goals | 1 | 2023 | 162 | 0.190 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 66 | 0.190 |
Why?
| | Patient Selection | 4 | 2018 | 665 | 0.190 |
Why?
| | Gene Fusion | 2 | 2018 | 24 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 67 | 0.190 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 139 | 0.190 |
Why?
| | Cell Proliferation | 7 | 2017 | 2347 | 0.190 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 164 | 0.190 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 33 | 0.190 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 237 | 0.180 |
Why?
| | Pheochromocytoma | 1 | 2022 | 57 | 0.180 |
Why?
| | Biopsy | 4 | 2018 | 1086 | 0.180 |
Why?
| | Trastuzumab | 1 | 2021 | 100 | 0.180 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1209 | 0.180 |
Why?
| | Carbazoles | 1 | 2021 | 84 | 0.180 |
Why?
| | Meningioma | 1 | 2022 | 81 | 0.180 |
Why?
| | Glioblastoma | 2 | 2015 | 322 | 0.180 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 14 | 0.170 |
Why?
| | Government Regulation | 1 | 2020 | 49 | 0.170 |
Why?
| | Pathology, Clinical | 2 | 2017 | 36 | 0.170 |
Why?
| | United States | 9 | 2020 | 13938 | 0.170 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 84 | 0.170 |
Why?
| | Piperidines | 1 | 2021 | 190 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 209 | 0.160 |
Why?
| | Stakeholder Participation | 1 | 2020 | 77 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 325 | 0.160 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 55 | 0.160 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 148 | 0.160 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 28 | 0.160 |
Why?
| | Smad4 Protein | 1 | 2019 | 37 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 51 | 0.160 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 57 | 0.150 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2023 | 491 | 0.150 |
Why?
| | Multigene Family | 1 | 2019 | 198 | 0.150 |
Why?
| | Pyridazines | 1 | 2018 | 50 | 0.150 |
Why?
| | Genetic Markers | 1 | 2019 | 339 | 0.150 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 580 | 0.150 |
Why?
| | Database Management Systems | 1 | 2018 | 48 | 0.150 |
Why?
| | Piperazines | 2 | 2018 | 337 | 0.150 |
Why?
| | Thromboembolism | 1 | 2018 | 102 | 0.150 |
Why?
| | Gene Frequency | 1 | 2019 | 504 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2019 | 361 | 0.140 |
Why?
| | Quinazolines | 3 | 2014 | 243 | 0.140 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 31 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 227 | 0.140 |
Why?
| | Smokers | 1 | 2018 | 138 | 0.140 |
Why?
| | Skin Neoplasms | 2 | 2020 | 833 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 229 | 0.140 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.140 |
Why?
| | Intraoperative Care | 1 | 2017 | 45 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 592 | 0.140 |
Why?
| | Gene Deletion | 1 | 2019 | 372 | 0.140 |
Why?
| | Retrospective Studies | 11 | 2025 | 14571 | 0.140 |
Why?
| | Medical Informatics | 1 | 2018 | 99 | 0.140 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 490 | 0.140 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 189 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 86 | 0.130 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 10 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 305 | 0.130 |
Why?
| | Coculture Techniques | 1 | 2017 | 225 | 0.130 |
Why?
| | Disease Progression | 6 | 2024 | 2613 | 0.130 |
Why?
| | RNA, Messenger | 4 | 2018 | 2676 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2017 | 209 | 0.130 |
Why?
| | Sulfonamides | 2 | 2017 | 500 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 68 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2016 | 117 | 0.130 |
Why?
| | Codon | 1 | 2016 | 86 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 70 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 191 | 0.120 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 84 | 0.120 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 87 | 0.120 |
Why?
| | Oncogene Proteins | 1 | 2015 | 52 | 0.120 |
Why?
| | Protein Kinases | 1 | 2017 | 309 | 0.120 |
Why?
| | Signal Transduction | 5 | 2017 | 4838 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2016 | 301 | 0.120 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 94 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1493 | 0.120 |
Why?
| | Liver Neoplasms | 3 | 2015 | 643 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 428 | 0.120 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 281 | 0.120 |
Why?
| | Medical Oncology | 3 | 2023 | 274 | 0.120 |
Why?
| | Hamartoma | 1 | 2015 | 20 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2016 | 267 | 0.120 |
Why?
| | Medicare | 1 | 2020 | 724 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 934 | 0.120 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 8 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 171 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 39 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 267 | 0.110 |
Why?
| | DNA Copy Number Variations | 4 | 2018 | 169 | 0.110 |
Why?
| | Deoxycytidine | 1 | 2015 | 164 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 558 | 0.110 |
Why?
| | Speech Disorders | 1 | 2014 | 34 | 0.110 |
Why?
| | Paresis | 1 | 2014 | 30 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 109 | 0.110 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1021 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2020 | 1109 | 0.110 |
Why?
| | Lung Transplantation | 1 | 2016 | 276 | 0.110 |
Why?
| | Receptor, trkA | 1 | 2013 | 16 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 313 | 0.110 |
Why?
| | Alternative Splicing | 3 | 2017 | 218 | 0.110 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 166 | 0.110 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 930 | 0.110 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 78 | 0.110 |
Why?
| | Microscopy, Electron | 1 | 2014 | 417 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 1945 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 283 | 0.110 |
Why?
| | Sarcoma | 1 | 2015 | 177 | 0.100 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 117 | 0.100 |
Why?
| | Societies, Medical | 4 | 2018 | 749 | 0.100 |
Why?
| | Graft Rejection | 1 | 2016 | 558 | 0.100 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 89 | 0.100 |
Why?
| | Headache | 1 | 2014 | 138 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 940 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1353 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 231 | 0.100 |
Why?
| | Tissue Fixation | 1 | 2012 | 34 | 0.100 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 190 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 634 | 0.100 |
Why?
| | Gene Amplification | 3 | 2019 | 103 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 1943 | 0.100 |
Why?
| | Lung | 4 | 2015 | 3752 | 0.100 |
Why?
| | Mutation Rate | 1 | 2011 | 25 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 439 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 98 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1621 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2541 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 187 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 165 | 0.090 |
Why?
| | Teratoma | 1 | 2011 | 103 | 0.090 |
Why?
| | Epithelial Cells | 1 | 2017 | 1036 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2012 | 200 | 0.090 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 97 | 0.090 |
Why?
| | Prospective Studies | 2 | 2023 | 7079 | 0.090 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1423 | 0.090 |
Why?
| | Genome, Human | 1 | 2012 | 392 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2150 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 813 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1687 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 206 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 68 | 0.080 |
Why?
| | Survival Rate | 4 | 2019 | 1875 | 0.080 |
Why?
| | Disease-Free Survival | 3 | 2016 | 656 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2012 | 332 | 0.080 |
Why?
| | Telomere | 3 | 2000 | 226 | 0.080 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 13 | 0.070 |
Why?
| | beta Catenin | 2 | 2023 | 219 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 29 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 574 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1417 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 4915 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 194 | 0.070 |
Why?
| | Heart Neoplasms | 1 | 2008 | 49 | 0.070 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 878 | 0.070 |
Why?
| | Adolescent | 6 | 2019 | 20301 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1392 | 0.070 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3033 | 0.070 |
Why?
| | Workflow | 2 | 2017 | 155 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1061 | 0.060 |
Why?
| | Eye Neoplasms | 1 | 2005 | 16 | 0.060 |
Why?
| | Mental Disorders | 1 | 2014 | 1010 | 0.060 |
Why?
| | Pleura | 1 | 2024 | 22 | 0.060 |
Why?
| | Immunophenotyping | 1 | 2005 | 312 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 759 | 0.060 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 70 | 0.050 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 33 | 0.050 |
Why?
| | DNA Polymerase II | 1 | 2023 | 38 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 41 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 326 | 0.050 |
Why?
| | Genes, ras | 2 | 2015 | 98 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 47 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 37 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 328 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1169 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 47 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 581 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1077 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3383 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 113 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 1000 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 360 | 0.050 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 283 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1689 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1483 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 71 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2135 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 450 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 6518 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 760 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 45 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 622 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 579 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 217 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 33 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 179 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5407 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 55 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2737 | 0.040 |
Why?
| | RNA, Untranslated | 1 | 1999 | 114 | 0.040 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 29 | 0.040 |
Why?
| | Phthalazines | 1 | 2018 | 40 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 108 | 0.040 |
Why?
| | Cetuximab | 1 | 2018 | 94 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 24 | 0.040 |
Why?
| | Breast | 1 | 2018 | 153 | 0.040 |
Why?
| | Diarrhea | 1 | 2018 | 177 | 0.030 |
Why?
| | Child | 5 | 2015 | 20805 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 156 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 58 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 531 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2819 | 0.030 |
Why?
| | Pathology, Surgical | 1 | 2016 | 8 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 320 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 64 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 358 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 214 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1403 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 17 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 10450 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 683 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 48 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 140 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 129 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 76 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 90 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1496 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 638 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 687 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 773 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 306 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 166 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 127 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1003 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 371 | 0.030 |
Why?
| | Animals | 5 | 2019 | 34600 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 15 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 764 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 169 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 758 | 0.030 |
Why?
| | Disease Management | 1 | 2017 | 593 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 421 | 0.030 |
Why?
| | Syndecan-4 | 1 | 2012 | 7 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2013 | 113 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1363 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2015 | 427 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 883 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 302 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 29 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2635 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 326 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 382 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 115 | 0.020 |
Why?
| | Mice | 2 | 2019 | 16644 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 318 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 391 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 208 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 6375 | 0.020 |
Why?
| | Infant | 2 | 2015 | 8992 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 811 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 497 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 291 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2065 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 97 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 18 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 836 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4010 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1243 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1953 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 5 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 311 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 28 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 510 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2715 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 761 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1924 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1044 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 125 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3058 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2438 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3896 | 0.020 |
Why?
| | Fibroblasts | 2 | 2000 | 939 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1632 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 5739 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 5 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 16 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 91 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 41 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 21 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 267 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 231 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 10 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 49 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 47 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 169 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 896 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 180 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 172 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 144 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 421 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 178 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 471 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1284 | 0.010 |
Why?
| | Skin | 1 | 2000 | 719 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1142 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 1013 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|